Moderna Inc. reported first-quarter earnings that surpassed analyst expectations, with earnings per share of $(3.07) beating estimates of $(3.55) and sales totaling $167 million, exceeding the forecast of $97.5 million. The company's revenue, however, saw a significant decline of 91% compared to the previous year, primarily due to a drop in Covid vaccine sales. Despite the decline, the revenue still topped expectations. Moderna's Spikevax vaccine generated $167 million in sales, including $100 million in U.S. sales and $67 million internationally. The company also announced plans to launch an RSV vaccine in the fall.
$MRNA now up 10%, holy smokes https://t.co/CxSgg2dsIE
Moderna Shares Jump After Better-Than-Expected Sales -- WSJ 😀 https://t.co/v0ilNoHpzy
$MRNA #weekly breakout today Covid Sales are still a thing seems like! https://t.co/uQyWOxrMUo
$MRNA up 7% now Had to cringe writing it up bullish last week, but paid off, loved its recent price action https://t.co/wzj2pflwWp
Moderna $MRNA beats estimates in Q1 2024, targets RSV vaccine launch in fall https://t.co/ZXFya1X2eX https://t.co/e6qEv5zhy4
Moderna quarterly sales beat expectations https://t.co/CUBRDGfVAY https://t.co/cw8fSVHnF7
$MRNA -- revenue down 91% in Q1 as Covid vaccine sales go pffffft. They're going to need some pipeline wins. https://t.co/LlDM8dHwye
Moderna revenue dives by 91% but tops analyst expectations https://t.co/0dhIUtpIrw
$MRNA Q1 2EPS $(3.07) beats $(3.55) Est. Sales $167M beat $97.5M Est. $167M in Spikevax sales, which includes $100M U.S. sales and $67M in international sales. Cash, cash equivalents $12.2B
Moderna Results Beat Estimates as Company Prepares for RSV Shot Launch https://t.co/gS8C4qBTIv